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ABSTRACT
We evaluated the safety and toxicity through a 5-cohort dose-modification model of once-daily administration of IV
busulfan (Bu) in combination with high-dose cyclophosphamide (Cy) as preparative therapy for stem cell trans-
plantation. Twenty-one adult patients with hematologic malignancies were evaluated. Eleven patients underwent
autologous and 10 patients underwent HLA-matched sibling allogeneic transplantation. Patients were sequentially
enrolled into 5 cohorts. Cohort 1 received intravenous (IV) Bu 1.6 mg/kg every 12 hours for 2 doses and then 0.8
mg/kg every 6 hours for 12 doses; cohort 2 received IV Bu 1.6 mg/kg every 12 hours for 4 doses and then 0.8 mg/kg
every 6 hours for 8 doses; cohort 3 received IV Bu 3.2 mg/kg for 1 dose and then 1.6 mg/kg every 12 hours for 2
doses and 0.8 mg/kg every 6 hours for 8 doses; cohort 4 received IV Bu 3.2 mg/kg every 24 hours for 2 doses and
then 0.8 mg/kg every 6 hours for 8 doses; and cohort 5 received IV Bu 3.2 mg/kg every 24 hours for 4 doses. In all
groups, Bu was administered on day7 through day4 and was followed at least 6 hours after the last Bu dose by
Cy 60 mg/kg daily for 2 doses on days 3 and 2. Blood samples were collected for pharmacokinetic analysis on
the first and last day of IV Bu administration. All patients were alive and had engrafted at day 30. Five patients
developed grade 3 or 4 toxicities. Four patients developed hepatic abnormalities, and 3 exhibited evidence of
veno-occlusive disease. Two of 3 patients in cohort 5 with a Bu area under the curve >6000 mol/min developed
autopsy-confirmed veno-occlusive disease. Interpatient variability in AUCs was observed in patients within and
between cohorts, but no statistically significant interpatient differences were observed in Bu half-life, volume of
distribution, clearance, or dose-adjusted area under the curve. Further, minimal variability in Bu pharmacokinetics
was observed between the 2 evaluations performed in each patient, thus reflecting the stability of Bu disposition
within individual patients. On the basis of the dosing guidelines and schedule outlined in this study, our data suggest
that administration of IV Bu 3.2 mg/kg IV every 24 hours for 4 doses in combination with Cy may result in excessive
toxicity.
© 2004 American Society for Blood and Marrow Transplantation
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ENTRODUCTION
The availability of an intravenous (IV) formulation
f busulfan (Bu) combined with the desire to shift care
o the outpatient setting led to the investigation of
14lternative Bu administration schedules other than the
-times-daily dosing schedule often used. Studies in
atients undergoing BMT for hematologic malignan-
ies suggest that IV Bu (IV Busulfex; ESP Pharma,
dison, NJ) is associated with similar outcomes and
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Dose-Modification Protocol for Hematologic Malignancies
Boxicities when used instead of oral Bu as a compo-
ent of the preparative regimen [1-8]. In addition,
vailable information suggests that the incidence of
epatic veno-occlusive disease (VOD) may be lower in
atients receiving IV Bu as compared with oral Bu
5-8].
Bu, a bifunctional alkylating agent, is often com-
ined with cyclophosphamide (Cy) for conditioning of
atients undergoing allogeneic or autologous hema-
opoietic stem cell transplantation [1-3,5-15]. The
tandard oral BuCy2 regimen includes the administra-
ion of Bu at a dose and schedule of 1.0 mg/kg every
hours for 16 doses and Cy 60 mg/kg daily for 2
oses.
Attempts at developing an IV preparation of Bu
ere initially limited because of the drug’s poor aque-
us solubility; however, several formulations have
een investigated, including a formulation developed
y Andersson et al. [16] that uses dimethyl acetamide
nd polyethylene glycol (IV Busulfex); it became com-
ercially available in 1999. Data from the phase I trial
f Andersson et al. determined that an IV Bu dose of
.8 mg/kg provided systemic exposure similar to the
ystemic exposure obtained after a standard oral dose
f 1 mg/kg [17]. Pharmacokinetic (PK) data from a
hase II trial [8] in which patients with advanced
ematologic malignancies were treated with 16 doses
f IV Bu 0.8 mg/kg followed by 2 daily IV doses of Cy
0 mg/kg showed that the regimen was well tolerated
nd demonstrated a more consistent PK proﬁle than
hat reported with oral Bu.
The purpose of this investigation was to evaluate
he safety and tolerability of a modiﬁed dosing regi-
en of IV Bu combined with high-dose IV Cy.
hrough a dose-modiﬁcation strategy involving 5
nique Bu dose cohorts, we investigated the potential
o administer IV Bu once daily for 4 days (cohort 5) in
ombination with Cy as the preparative regimen be-
ore bone marrow transplantation for hematologic
alignancies. PK proﬁles associated with each dosing
chedule are reported.
ATIENTS AND METHODS
ligibility Criteria
Patients with hematologic malignancies who were
6 to 60 years old and without a previous stem cell
ransplantation were eligible if they were in complete
emission but had a high risk of relapse or if they had
elapsed or refractory disease. Patients older than 60
ears of age with a good performance status and min-
mal comorbidities were considered for enrollment on
n individual basis. Patients were required to have a
ife expectancy longer than 12 weeks and could not be
everely limited by concomitant illness. Patients were
xcluded if they had any of the following: (1) a serum s
B&MTreatinine of 2.0 mg/dL, (2) a serum bilirubin
1.5  the upper limit of normal, (3) evidence of
epatitis or cirrhosis, (4) abnormal pulmonary func-
ion, (5) a cardiac left ventricular ejection fraction
40%, and (6) human immunodeﬁciency virus sero-
ositivity. Patients receiving autologous transplants
ust have collected a minimum of 2.5  106 CD34
ells per kilogram during peripheral blood stem cell
obilization. Patients undergoing allogeneic trans-
lantation were required to have granulocyte colony-
timulating factor–mobilized peripheral blood pro-
enitor cells or bone marrow from an HLA-matched
elated donor available. The study protocol was ap-
roved by the Institutional Review Board for Human
ubject Investigation from each of the participating
tudy sites, and written, informed consent was ob-
ained from each patient.
onditioning Regimen
Patients were hospitalized during IV Bu adminis-
ration to facilitate observation of toxicities and PK
onitoring. Patients were consecutively assigned to
ose cohorts 1 through 5. IV Bu was given according
o the designated cohort schedule and infusion rate
eginning on day 7. Cy 60 mg/kg was given IV over
hours for 2 consecutive days beginning on day 3,
o sooner than 6 hours after the last IV Bu dose.
oses for both Bu and Cy were based on the lesser of
ctual or adjusted ideal body weight [18].
ose-Modification Schedule
Each cohort was to consist of 4 patients. All pa-
ients within a cohort were monitored for a minimum
f 30 days after stem cell infusion to assess safety and
nitial efﬁcacy. The last patient within a cohort must
ave completed the monitoring period of 30 days after
tem cell infusion before proceeding to the next co-
ort. In the event that 1 of the following dose-limiting
oxicities occurred within a cohort during the moni-
oring period, an additional 2 patients were added to
he speciﬁed cohort before advancing to the next co-
ort: (1) seizures considered related to Bu; (2) severe
OD, as deﬁned by death due to VOD or lack of
esolution or improvement of VOD by day 30; (3)
rade 4 gastrointestinal toxicity related to Bu; (4)
elayed neutrophil engraftment related to Bu, deﬁned
y lack of achievement of absolute neutrophil count
500 by day 28; and (5) an unexpected grade 4 or
ife-threatening toxicity related to Bu. If no dose-
imiting toxicity occurred in the 2 additional patients,
e advanced to the next Bu dose cohort. If 2 or more
ose limiting toxicities occurred within a Bu dose
ohort, then subsequent patients were enrolled in the
revious cohort. The maximally tolerated IV Bu dos-
ng schedule was then deﬁned as the cohort dose
chedule below the cohort in which 2 or more dose
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6imiting toxicities occurred with at least 6 patients
tudied.
upportive Care
Phenytoin was administered as seizure prophylaxis
efore and during Bu treatment in all patients. Mesna,
ntiemetics, blood products, and other supportive care
easures were used according to institutional guide-
ines and at the discretion of the attending physician as
eemed necessary by a patient’s disease history and
isk factors. For patients undergoing allogeneic trans-
lantation, cyclosporine and short-course mini-meth-
trexate were used as graft-versus-host disease pro-
hylaxis [19,20].
K Analysis
Multiple timed blood samples (5 mL) for Bu PK
nalysis were obtained from each patient. The time
nd quantity of samples obtained were dependent on
hich Bu dose cohort each patient was participating
n. The IV Bu dose regimen for each of the 5 dose
ohorts is outlined in Table 1. In all cohorts, samples
ere collected on day 7 and day 4. On day 7,
amples were collected around dose 1, regardless of
able 1. Dosing Schedules*
ohort 1
Day 7 1.6 mg/kg IV (over 4 h) q12h  2 doses
Day 6 0.8 mg/kg IV (over 2 h) q6h  4 doses
Day 5 0.8 mg/kg IV (over 2 h) q6h  4 doses
Day 4 0.8 mg/kg IV (over 2 h) q6h  4 doses
ohort 2
Day 7 1.6 mg/kg IV (over 2 h) q12h  2 doses
Day 6 1.6 mg/kg IV (over 4 h) q12h  2 doses
Day 5 0.8 mg/kg IV (over 2 h) q6h  4 doses
Day 4 0.8 mg/kg IV (over 2 h) q6h  4 doses
ohort 3
Day 7 3.2 mg/kg IV (over 4 h) q24h  1 dose
Day 6 1.6 mg/kg IV (over 2 h) q12h  2 doses
Day 5 0.8 mg/kg IV (over 2 h) q6h  4 doses
Day 4 0.8 mg/kg IV (over 2 h) q6h  4 doses
ohort 4
Day 7 3.2 mg/kg IV (over 4 h) q24h  1 dose
Day 6 3.2 mg/kg IV (over 4 h) q24h  1 dose
Day 5 0.8 mg/kg IV (over 2 h) q6h  4 doses
Day 4 0.8 mg/kg IV (over 2 h) q6h  4 doses
ohort 5
Day 7 3.2 mg/kg IV (over 4 h) q24h  1 dose
Day 6 3.2 mg/kg IV (over 4 h) q24h  1 dose
Day 5 3.2 mg/kg IV (over 4 h) q24h  1 dose
Day 4 3.2 mg/kg IV (over 4 h) q24h  1 dose
2h indicates every 12 hours.
Doses are based on the lesser of actual or adjusted body weight.
Ideal body weight [18]: male (kg), 56.2  (1.41  No. inches
over 60); female (kg) 53.1  (1.36  No. inches over 60).
Adjusted body weight: 0.25 (total body weight  ideal body
weight)  ideal body weight.ohort. On day 4, samples were collected around Bu u
16ose 11 for cohort 1, dose 9 for cohort 2, dose 8 for
ohort 3, dose 7 for cohort 4, and dose 4 for cohort 5.
The PK parameter estimates for Bu were deter-
ined by using standard noncompartmental methods
21] with Kinetica version 4.1 (Innaphase Corp.,
hamps-sur-Marne, France). For each patient, plasma
u concentrations were plotted against time on a
emilogarithmic scale. The peak Bu plasma concen-
ration and time to peak concentration were deter-
ined directly from the plasma concentration/time
urves. The area under the curve (AUC) was obtained
y using the linear trapezoidal rule up to the ﬁnal
easured concentration and was extrapolated to in-
nity by using  after the ﬁrst dose and to the end of
he dosing interval (t) under multidose conditions.
he elimination half-life (t1⁄2) was determined from
he postdistributive terminal portion of the plasma
oncentration/time curve.
Total body clearance (Cl) was determined with the
ormula dose/AUC0-infinity after the ﬁrst dose and
ose/AUC0-t under multidose conditions.
The apparent steady-state volume of distribution
Vdss) was determined with the following equation:
Vdss [(dose)(AUMC)]/AUC
2 [(dose)(T)/(AUC)(2)]
here AUMC is the area under the ﬁrst moment of
he concentration/time curve and T is the infusion
uration.
ample Preparation
A 0.2-mL plasma sample was added to a borosili-
ate glass tube containing 0.04 mL of internal stan-
ard and vortexed; 0.5 mL of methanol was added and
ortexed again for 10 seconds. The samples were de-
ivatized by using a modiﬁcation of the method of
ifai et al. [22] by adding 0.15 mL of 5% diethyldi-
hiocarbamate and vortexing for 10 seconds. To this
ample, 0.5 mL of ultrapure water was added and
ortexed for 10 seconds, after which 2 mL of ethyl
cetate was added. The tube was covered with alumi-
um foil and capped, vortexed for 1 minute, and cen-
rifuged at 4000 rpm for 2 minutes. The supernatant
as transferred to a clean borosilicate tube with the
ontents dried under nitrogen at 40°C by using a
ymark Turbo Vap Evaporator (Zymark, Hopkinton,
A), resuspended in 0.05 mL of butanol, and trans-
erred to a clean vial. Subsequently 1 L was injected
nto a Varian 3400 gas chromatograph (Varian, Wal-
ut Creek, CA) equipped with a thermionic speciﬁc
etector (nitrogen/phosphorous detector) and an 8100
utosampler. A Varian 1077 split/splitless injector at
70°C and a Restek Cyclosplitter inlet sleeve (Restek,
ellefonte, PA) were used; the injector was operated
n the splitless mode. Analysis was performed with a
&W Scientiﬁc capillary DB5 mass spectrometry col-
mn (30 m  0.25 mm) with a ﬁlm thickness of 0.25

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Dose-Modification Protocol for Hematologic Malignancies
Bm (J&W Scientiﬁc, Folsom, CA). UHP helium
Matheson Gas Products, Parsippany, NJ) was used as
arrier gas at a ﬂow rate of 4.3 mL/min. The thermi-
nic speciﬁc detector was set at 280°C with ﬂow rates
f 4.6 mL/min for hydrogen and 169 mL/min for air.
he initial oven temperature was maintained at 150°C
or 1.5 minutes and was then increased 25°C/min to
60°C with a hold time of 2.6 minutes, followed by a
econd increase of 25°C/min to 280°C with a hold
ime of 10.3 minutes. Standards were prepared from a
tock solution, 2 mg Bu per milliliter of acetone, that
as immediately diluted 10:1 in methanol. Bu and
odium diethyldithiocarbamate trihydrate were ob-
ained from Aldrich Chemical Company (St. Louis,
O). Internal standard—1,6-bis-(methane sulfonly-
xy) hexane—was synthesized by a modiﬁcation of
he method of Rifai et al. [22]. Ethyl acetate, metha-
ol, n-butyl alcohol, and acetone were obtained from
oneywell Burdick and Jackson (Muskegon, MI), and
ll were high-performance liquid chromatography
rade. Internal standard (0.05 mg Bu per milliliter
ethanol) was prepared by the addition of 3.8 mL of
ethanol to 200 L of stock solution. A 5% diethyl-
ithiocarbamate solution was prepared daily in ultra-
ure water. Bu analysis in plasma was linear to 5.0
g/mL. The within-day mean coefﬁcient of variation
as 1.41%, and the mean SD was 0.017 (n  24). For
he between-day variance, triplicate plasma standard
urves yielded mean correlation coefﬁcients of 0.9991,
.9993, and 0.9996. The between-day mean coefﬁ-
ient of variation was 2.43%, and the mean SD was
.045 (n  24).
tatistical Analysis
PK parameter estimates and demographic data
ere examined univariately and graphically to deter-
ine distributional characteristics. Bu AUC and peak
lasma concentration were normalized for each sub-
ect by dividing the parameter by the Bu dose per
ilogram administered. The effect of cohort and time
n these parameters, as well as Cl corrected for
eight, was tested by using a mixed model approach
hat allows for a possible within-subject correlation
cross time. An interaction term of time and cohort
as also added to the model. If the AUCs were pro-
ortional to the dose, then one would not expect to see
cohort effect with this analysis. Differences between
rst-dose and multidose Bu PK parameter estimates
ere tested as post hoc contrasts in the mixed model.
epatic VOD Diagnosis and Evaluation
A clinical diagnosis of VOD was made by the treat-
ng physician after clinical examination and laboratory
ndings were analyzed. Diagnosis was based on the cri-
eria of Jones et al. [23] and assigned a severity grade
ased on the criteria of Bearman et al. [24]. t
B&MTESULTS
atient Characteristics
Clinical data are presented on 21 patients with
ematologic malignancies treated at 3 institutions be-
ween August 2000 and September 2002. Patient char-
cteristics are listed in Table 2. The median age was
7 years (range, 26-66 years), and there were 12 men
nd 9 women. Eleven patients underwent autologous
ransplantation: 8 for non-Hodgkin lymphoma, 1 each
or acute myelogenous leukemia (AML), Hodgkin dis-
ase, and multiple myeloma. Ten patients underwent
llogeneic transplantation: 3 for non-Hodgkin lym-
homa, 3 for chronic myelogenous leukemia (CML),
for myelodysplastic syndrome (MDS), 1 for AML,
nd 1 for myeloproliferative disease. Five patients
ere in complete remission at the time of transplan-
ation. Fifteen patients (71%) had received at least 2
herapies before transplantation, and 9 patients had
elapsed or refractory disease at the time of transplan-
ation. The 3 CML patients were in chronic phase,
nd 2 patients were newly diagnosed with MDS and
yeloproliferative disease. The patient with multiple
yeloma had stable disease.
All patients were alive at day 30. Neutrophil
ngraftment (absolute neutrophil count 500/L)
ccurred at a median of 14 days (14 days for autol-
gous and 15 days for allogeneic transplantations).
he median time to a sustained platelet count of
20000/L was 19 days (20 days for autologous and
9 days for allogeneic transplantations). Three pa-
ients received granulocyte colony-stimulating fac-
or to speed up neutrophil engraftment. One patient
ith chronic phase CML initially engrafted plate-
ets on day 0 (platelet nadir 30000), on the basis of
he International Bone Marrow Transplant Registry
eﬁnition of engraftment [25], but later the platelet
ount decreased, and the patient was transfusion
ependent starting on day 25. The patient later died
rom complications related to the development of
OD.
usulfan Pharmacokinetics
The results of the Bu PK evaluation are shown
n Table 3. Interpatient variability in Bu disposition
as observed for the Bu PK parameter estimates t1⁄2,
olume of distribution, Cl, and dose-adjusted AUC.
his variability in Bu disposition parameters was
bserved between patients within the same dose
ohort as well as between patients in each of the 5
ose cohorts. However, no statistically signiﬁcant
ifferences in Bu t1⁄2, volume of distribution, Cl, or
ose-adjusted AUC were observed between dose
ohorts. Although a large degree of interpatient
ariability was observed in Bu disposition, intrapa-
ient Bu PK remained relatively constant between
he ﬁrst and second PK analysis for individual pa-
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6ients (data not shown). With the exception of AUC
n cohort 5, no relationship was observed between
u PK parameter estimates and patient toxicity. As
xpected, and reﬂecting the dose administered, the
patients enrolled in cohort 5 had the greatest Bu
UC. In cohorts 3, 4, and 5, a total of 7 patients had
u AUC 5000 mol/min, and 5 patients exhibited
o signiﬁcant toxicities.
oxicity
Most toxicities were grade 1 and 2, including
ausea, vomiting, diarrhea, fatigue, and mucositis.
ive patients developed grade 3 or greater toxicities,
of which resulted in death. One patient had a
eizure assumed to be from herpetic encephalitis
nd subsequently developed complications relating
o toxic epidermal necrolysis; this patient died on
ay 40. Four patients developed hepatic abnormal-
ties, and 3 exhibited evidence of VOD. Of these 4
atients, the only patient in the group who was not
iagnosed with VOD was enrolled in cohort 4. This
atient (maximum Bu AUC, 6272 mol/min) devel-
ped biopsy-conﬁrmed drug-induced hepatitis on
ay 22, which resulted in a maximum aspartate
minotransferase level of 1332 U/L. Of the 3 pa-
able 2. Patient Characteristics
Patient No. Age (y) Disease
Cohort 1
01-001 26 NHL
01-002 40 AML
01-103 52 MDS
02-104 66 NHL
Cohort 2
02-201 45 MM
01-202 59 NHL
03-203 55 AML
01-204 30 HD
Cohort 3
01-301 29 NHL
03-302 61 NHL
02-303 49 NHL
02-304 46 CML
Cohort 4
01-401 39 MPD
03-402 64 NHL
03-403 51 NHL
02-404 59 NHL
02-405 48 CML
02-406 46 NHL
Cohort 5
02-501 46 MDS
02-502 33 CML
01-503 52 NHL
ML indicates acute myelogenous leukemia; Allo, allogeneic; Auto
remission; CR2, second complete remission; CR3, third complet
multiple myeloma; MPD, myeloproliferative disease; NHL, non
Allo, allogeneic; Auto, autologous; CMML, chronic myelomonients with VOD, 1 patient enrolled in cohort 2 4
18eveloped moderate clinical VOD on day 18 (max-
mum total bilirubin, 18 mg/dL; maximum Bu
UC, 2062 mol/min), which resolved without
reatment. The remaining 2 cases of VOD occurred
n patients enrolled in cohort 5. One patient (max-
mum Bu AUC, 6380 mol/min) with VOD—based
n a maximum total bilirubin of 32.7 mg/dL, jaun-
ice, ascites, weight gain, and right upper quadrant
ain—was diagnosed with VOD on day 40 and died
n day 51. Autopsy and liver biopsy results con-
rmed the diagnosis of VOD. The other cohort 5
atient (maximum Bu AUC, 6198 Mol-min) was
iagnosed as having moderate VOD on day 17. This
as further deﬁned as severe VOD because of a lack
f resolution by day 30. The same patient also
xperienced a grade 3 paralytic ileus and later died.
Five patients had a measured Bu AUC 6000
mol/min. Three of the patients were in cohorts 3
nd 4, in which the AUC was the highest after day 1
f Bu. The remaining 2 patients were in cohort 5, in
hich the AUC was highest on day 4 of Bu. Both
atients in cohort 5 developed VOD, whereas the
ther 3 patients did not. In contrast, the patient in
ohort 5 who did not develop VOD had Bu AUCs of
573 mol/min on day 1 and 5391 mol/min on day
Pre-BMT Status Type of BMT
Primary refractory Auto PBSCT
CR1 Auto PBSCT
CMML Allo PBSCT
First relapse Auto PBSCT
Stable disease Auto PBSCT
CR1 Auto PBSCT
Primary refractory Allo PBSCT
Second relapse Auto PBSCT
CR1 Auto PBSCT
CR3 Auto PBSCT
CR2 Allo PBSCT
First chronic phase Allo PBSCT
New diagnosis Allo PBSCT
Primary refractory Auto PBSCT
CR2 Auto PBSCT
Relapsed refractory Allo PBSCT
First chronic phase Allo PBSCT
Primary refractory Allo PBSCT
New diagnosis Allo PBSCT
First chronic phase Allo PBSCT
Relapsed refractory Auto PBSCT
ogous; CML, chronic myelogenous leukemia; CR1, ﬁrst complete
sion; HD, Hodgkin disease; MDS, myelodysplastic syndrome; MM,
kin lymphoma; PBSCT, peripheral blood stem cell transplantation;
eukemia; BMT, bone marrow transplantation., autol
e remis
-Hodg
ocytic l(Table 4).
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BBISCUSSION
Although the standard oral BuCy2 regimen is ef-
ective, it is often not well tolerated. Oral Bu is avail-
ble in the United States only as a 2-mg tablet. This
equires patients to ingest large numbers of pills with
ach dose. Administration can be eased by repackag-
ng the tablets, but ingestion remains difﬁcult, partic-
larly if the patient is nauseated or has difﬁculty swal-
owing. The PK proﬁle of orally administered Bu
emonstrates wide interpatient and intrapatient vari-
bility due to age-related differences, alterations in
bsorption, circadian variations, drug-drug and drug-
ood interactions, and patient-speciﬁc parameters [26-
1]. PK studies with oral Bu demonstrate variations as
igh as 50% in calculated PK parameter estimates and
ay not be calculable in up to 20% of patients because
f slow absorption, delayed elimination, or both [26-
8]. Although the practice of ﬁrst-dose Bu PK analysis
irecting subsequent dosing for an individual treat-
ent course is routine at many centers, common
roblems with sampling and monitoring of oral Bu
nderscore the need for alternate methods of drug
elivery that provide more consistent and reliable Bu
isposition and systemic exposure.
Initial BuCy regimens required Bu to be adminis-
ered 4 times daily. Similar to the oral Bu dosing
trategies, initial IV Bu studies used the same dosing
trategy (ie, every-6-hour dosing) and have demon-
trated predictable and consistent PK proﬁles with
cceptable toxicity [1-3,5-8,17]. The data presented
ere with IV Bu dosing across the range studied con-
rm the overall intrapatient consistency and predict-
bility of IV Bu PK. Once-daily IV Bu dosing would
eem to be more convenient for the patient, possibly
llowing for outpatient transplantations, and could be
qually effective if overall Bu exposure were compa-
able to standard oral Bu dosing regimens.
The primary objective of this study was to assess
he safety, by using a dose-modiﬁcation cohort sched-
le, of once-daily IV Bu in combination with high-
ose IV Cy as the preparative regimen for patients
ndergoing autologous or allogeneic stem cell trans-
lantation. We found that once-daily administration
f high-dose IV Bu in combination with Cy was as-
ociated with an increased risk of liver toxicity and the
evelopment of VOD. Patients in cohorts that used
onventional every-6-hour IV Bu dosing after the in-
estigational portion of the dosing regimen tolerated
he preparative regimen better. However, on the basis
f our study protocol and the apparently dispropor-
ionate increase in observed adverse effects (VOD) for
ohort 5 patients, we believed it prudent and appro-
riate after enrolling 3 patients to discontinue enroll-
ent.
Data from PK evaluations after oral Bu givenevery 6 hours indicated that increased Bu exposureT C C T t V C A A A T D
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6as associated with an increased risk for VOD and
lso with other regimen-related toxicities [30-35].
opelan et al. [30,36] demonstrated that patients who
ad received more extensive chemotherapy before
ransplant were at greater risk for the development of
OD as a result of having higher Bu AUC. Patients
eceiving antileukemic therapy (induction/consolida-
ion) before allogeneic bone marrow transplantation
lso showed a greater chance of developing severe
OD than patients without therapy before transplan-
ation [37]. This study was not designed to examine or
orrelate pretransplantation treatment and risk of de-
eloping VOD. However, patients who developed he-
atic abnormalities, VOD, or both had at least 1 risk
actor (heavy pretreatment; induction/consolidation
or leukemia), as reported previously [30-37].
Excessive systemic exposure to Bu has been asso-
iated with higher morbidity and mortality [36]. In
his study, dose cohorts 1 through 4 received higher
able 4. Treatment-Related Risk Factors for the Development of VOD
atent No. Pre-BMT Trea
Cohort 1
01-001 ABVD  8 cycles, ESHAP  2 cycles
01-002 3-drug induction and Cy/VP/G-CSF mobilization
01-103 No prior treatment
02-104 CHOP  8 cycles, MINE  3 cycles
Cohort 2
02-201 VAD  4 cycles, Cy/G-CSF mobilization
01-202 CHOP  6 cycles
03-203 Ida/ARA-C induction and high-dose ARA-C consol
01-204 ABVD  10 cycles, ESHAP  2 cycles, Cy/GCSF m
Cohort 3
01-301 CHOP  4 cycles, RICE  2 cycles
03-302 M-BACOD  10 cycles, CHOP  10 cycles
02-303 CHOP  4 cycles, MINE  6 cycles, rituximab  4
02-304 No prior treatment
Cohort 4
01-401 Local XRT
03-402 Left nephrectomy and adrenalectomy, splenectom
rituximab  5 cycles, Cy/VP mobilization
03-403 CVP  10 cycles, rituximab  8 cycles, FNP  2 c
02-404 CVP  4 cycles, fludarabine  12 cycles, DHAP 
CHOP  3 cycles
02-405 Hydroxyurea  2 mo
02-406 R-CHOP  7 cycles, ESHAP  2 cycles, XRT to sp
Cohort 5
02-501 Mitomycin/5-FU  2 cycles, XRT to pelvis, abdom
02-502 Imatinib  2 mo
01-503 R-CHOP  8 cycles and Cy/VP/G-CSF mobilizatio
-CSF indicates granulocyte colony-stimulating factor; XRT, ra
ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; ESH
cyclophosphamide, etoposide, G-CSF; R-CHOP, cyclophosph
ifosfamide, mitoxantrone, etoposide; VAD, vincristine, doxorub
cyclophosphamide, vincristine, dexamethasone; RICE, rituxima
ARA-C, cytarabine; CVP, cyclophosphamide, vincristine, predn
sone, cytarabine, cisplatin.nitial doses of IV Bu; subsequent doses were consis- d
20ent with conventional Bu dosing. The observed inci-
ence of VOD and other toxicities in these ﬁrst 4 dose
ohorts was similar to what has been previously pub-
ished [5-8,17]. In contrast, 2 of 3 patients enrolled in
he cohort receiving 4 once-daily doses of IV Bu
eveloped severe VOD and died from regimen-re-
ated toxicity. In cohort 5, exposure to high Bu plasma
oncentrations was prolonged, as demonstrated by the
ncreased AUC concentrations on day 4 (dose 4) as
ompared with day 7 (dose 1). However, total Bu
xposure between cohorts was not signiﬁcantly dif-
erent.
A series of recently published articles [4-7] pre-
ented the clinical and pharmacologic experience of
V Bu administered in combination with either Cy or
udarabine. Studies by Russell et al. [4] and Fernandez
t al. [6] reported results with once-daily IV Bu. The
rst study reported the results observed in 70 patients
reated concurrently with once-daily IV Bu and ﬂu-
s)
Time Interval between
Last Dose of Bu and
First Dose of Cy
9 h
8 h
9 h
8 h
8 h
8 h
 1 10 h
ation, XRT to spine and mediastinum 8 h
8 h
7 h
, XRT to abdomen and pelvis 8.5 h
8 h
8 h
P  4 cycles, ESHAP  2 cycles, 4.5 h
5 h
s, rituximab  5 cycles, 8 h
8 h
8 h
gery 23.5 h
20 h
20 h
apy; 5-FU, 5-ﬂuorouracil; BMT, bone marrow transplantation;
poside, methylprednisolone, cytarabine, cisplatin; Cy/VP/G-CSF,
doxorubicin, vincristine, prednisone, rituximab; MINE, mesna,
xamethasone; M-BACOD, methotrexate, bleomycin, doxorubicin,
amide, carboplatin, etoposide; Ida/ARA-C, idarubicin, cytarabine;
FNP, ﬂudarabine, mitoxantrone, prednisone; DHAP, dexametha-tment(
idation
obiliz
cycles
y, CHO
ycles
2 cycle
ine
inal sur
n
diother
AP, eto
amide,
icin, de
b, ifosf
isone;arabine. Patients were dosed on the basis of ideal
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Body weight, and the IV Bu infusion was given over 3
ours. The investigators performed a detailed PK
nalysis in 12 patients; results showed remarkable con-
istency among patients, with no signiﬁcant differ-
nces in PK parameters between the ﬁrst and fourth
oses. No patient developed VOD, but 62 (88%) of 70
atients had transient bilirubin increases. Overall, the
ombination of IV Bu and ﬂudarabine seemed to be
ell tolerated.
An article by de Lima et al. [38] describes the
esults of using once-daily IV Bu in combination with
udarabine in 96 patients with either AML or MDS.
nly 2 cases of reversible VOD are reported. PK
nalysis showed that the once-daily IV Bu was cleared
n less than 24 hours without drug accumulation,
hich is supported by our results.
Fernandez et al. [6] reported the results of 12
atients treated with the combination of IV Bu and Cy
s preparative therapy. Six patients received twice-
aily IV Bu 1.6 mg/kg per dose for 8 doses, and the
ther 6 patients received once-daily IV Bu 3.2 mg/kg
er dose for 4 doses. All doses were infused over 4
ours and were based on actual body weight, with the
xception of 2 patients who received reduced doses
ecause of obesity. Hepatic abnormalities were seen in
patients; 1 of these patients developed VOD on day
3. The development of VOD in this patient was
ttributed to the administration of medroxyprogester-
ne acetate; the VOD resolved by day 43 after discon-
inuation of the drug. PK analysis demonstrated
ighly consistent and reproducible Bu PK parameters
n both cohorts.
The inconsistency between our outcomes and the
utcomes reported by Russell et al. [4], de Lima et al.
38], and Fernandez et al. [6] may be explained by
everal factors. One possible explanation is a loss of
inear Bu elimination in the patients receiving once-
aily dosing, with resulting increased Bu exposure and
oxicity. Patients in cohort 5 seemed to show de-
reased Bu Cl and drug accumulation from the ﬁrst
ose to the fourth dose. However, when AUC is
orrected for dose administered and allowing for usual
nterpatient variability, no statistically signiﬁcant con-
lusions can be made.
Another possible explanation is the potential ad-
itive toxicity from the combination of Bu and Cy. Cy
s already known to cause VOD [23,39], and the risk of
OD is of particular concern when Bu is used in
ombination. McDonald et al. [39] found a strong
orrelation between blood levels of various Cy metab-
lites and VOD.
Hassan et al. [40] showed that the metabolism of
y when used in combination with oral Bu greatly
nﬂuenced toxicity and outcome. When doses of Cy
ere given within 24 hours of the last dose of oral Bu,
rolonged exposure and decreased Cl of Cy were
bserved. The authors concluded that the hepatic de- T
B&MTletion of glutathione-S-transferase by Bu negatively
nﬂuences the PKs of Cy and ultimately leads to in-
reased toxicity.
In this study, all patients were required to receive
t least a 6-hour interval between the last dose of Bu
nd the ﬁrst dose of Cy, depending on the cohort.
wo patients received the ﬁrst dose of Cy without
aiting the entire 6 hours. This coincided with drug-
nduced hepatitis in 1 patient. This patient received
he ﬁrst dose of Cy 4.5 hours after the last dose of Bu.
In cohort 5, in which 2 of 3 patients died as a result
f complications related to VOD, all 3 patients re-
eived the ﬁrst dose of Cy without waiting a full 24
ours.
A third possible explanation is that pretransplan-
ation therapy signiﬁcantly inﬂuenced outcomes in
eavily pretreated patients. No patient received me-
roxyprogesterone acetate or gemtuzumab ozogami-
in, which have both previously been documented to
ncrease the risk of developing hepatic VOD [6,41].
ifteen (71%) of 21 patients were moderately to
eavily treated before transplantation. Four patients
19%) received 4 or more prior therapies. Of the 5
atients who developed grade 3 or greater toxicities, 3
ere considered heavily pretreated.
Multiple factors likely inﬂuenced the observed
utcomes in this study, most notably treatment before
ransplantation and the dosing interval between Bu
nd Cy. All of the patients who developed grade 3 or
reater toxicities were either pretreated, received Cy
arlier than directed after the ﬁnal dose of Bu, or both.
Our data suggest that the administration of IV Bu
.2 mg/kg every 24 hours for 4 doses in combination
ith Cy may result in excessive toxicity, presumably
ecause of increased Bu exposure. It seems probable
hat the observed intolerance was augmented by the
dministration of Cy, but the current data do not
ermit such analysis. In contrast, it seems that the
nce-daily administration of IV Bu in combination
ith ﬂudarabine is well tolerated [4,38].
The combination of once-daily IV Bu and Cy as
reparative therapy for transplantation should be done
ith caution and is not recommended unless it is part
f a clinical trial. Future studies examining once-daily
V Bu dosing in combination with Cy should evaluate
ncreasing the dosing interval between Bu and Cy to at
east 24 hours and potentially targeting lower Bu
UCs to improve outcomes and patient tolerability.
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